A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects

This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e. allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the relative bioavailability between a formulation only containing verinurad (i.e. verinurad prolonged release gelatin capsule 12 mg) and the FDC capsule.

开始日期2021-04-13

申办/合作机构

AstraZeneca PLC

[+1]

NCT04532918

/ Completed临床1期

An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin

This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will always be administered together with allopurinol.

开始日期2020-09-10

申办/合作机构

AstraZeneca PLC

[+1]

NCT04327024

/ Completed临床2期

A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction

International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction

开始日期2020-05-19

申办/合作机构

AstraZeneca PLC

100 项与 Verinurad 相关的临床结果

登录后查看更多信息

100 项与 Verinurad 相关的转化医学

登录后查看更多信息

100 项与 Verinurad 相关的专利（医药）

登录后查看更多信息

项与 Verinurad 相关的文献（医药）

2025-03-24·JACS Au

Structural Basis for Inhibition of Urate Reabsorption in URAT1

Article

作者: Bai, Yingjie ; Guo, Nianxin ; Fan, Junping ; Lei, Xiaoguang ; Ke, Han ; Wang, Haijun ; Zhang, Jing ; Xie, Wenjun ; Wang, Jin

The urate transporter 1 (URAT1) is the primary urate transporter in the kidney responsible for urate reabsorption and, therefore, is crucial for urate homeostasis. Hyperuricemia causes the common human disease gout and other pathological consequences. Inhibition of urate reabsorption through URAT1 has been shown as a promising strategy in alleviating hyperuricemia, and clinical and preclinical drug candidates targeting URAT1 are emerging. However, how small molecules inhibit URAT1 remains undefined, and the lack of accurate URAT1 complex structures hinders the development of better therapeutics. Here, we present cryoelectron microscopy structures of a humanized rat URAT1 bound with benzbromarone, lingdolinurad, and verinurad, elucidating the structural basis for drug recognition and inhibition. The three small molecules reside in the URAT1 central cavity with different binding modes, locking URAT1 in an inward-facing conformation. This study provides mechanistic insights into the drug modulation of URAT1 and sheds light on the rational design of potential URAT1-specific therapeutics for treating hyperuricemia.

2024-10-01·JAMA Cardiology

Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction

Article

作者: Kitzman, Dalane W. ; Mentz, Robert J. ; Sjöström, C. David ; Voors, Adriaan A. ; Shah, Sanjiv J. ; Källgren, Christian ; Lewis, Gregory D. ; Myte, Robin ; Perl, Shira ; Kaguthi, Grace

Importance:

Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors’ knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.

Objective:

To investigate the efficacy and safety of the novel urate transporter–1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.

Design, Setting, and Participants:

This was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024.

Interventions:

Eligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization.

Main Outcomes and Measures:

Key end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events).

Results:

Among 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro–brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, −59.6%; 95% CI, −64.4% to −54.2%) lowered SUA level to a greater extent than allopurinol (mean change, −37.6%; 95% CI, −45.3% to −28.9%) or placebo (mean change, 0.8%; 95% CI, −11.8% to 15.2%; P &lt; .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, −0.56 to 1.10 mL/kg/min; allopurinol, −0.17 mL/kg/min; 95% CI, −1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, −0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, −3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group.

Conclusions and Relevance:

Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.

Trial Registration:

ClinicalTrials.gov Identifier: NCT04327024

2024-05-01·Journal of the American Society of Nephrology : JASN

Combination Treatment with Verinurad and Allopurinol in CKD

Article

作者: Perl, Shira ; Bjursell, Magnus ; Rikte, Tord ; Stack, Austin G. ; Perkovic, Vlado ; Inker, Lesley A. ; Maklad, Noha ; Heerspink, Hiddo J.L. ; Sjöström, C. David ; Jongs, Niels ; Terkeltaub, Robert ; Eklund, Olof

Key Points:

The SAPPHIRE trial was designed to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with allopurinol in patients with CKD.Verinurad 3, 7.5, and 12 mg in combination with allopurinol 300 mg did not reduce albuminuria during 34 weeks treatment compared with allopurinol alone or placebo.Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo.

Background:

Hyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia.

Methods:

In this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dl, eGFR ≥25 ml/min per 1.73 m2, and a urinary albumin-creatinine ratio (UACR) 30–5000 mg/g to one of five treatment arms: placebo, placebo+allopurinol 300 mg/day, verinurad 3 mg+allopurinol 300 mg/day, verinurad 7.5 mg+allopurinol 300 mg/day, or verinurad 12 mg+allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary end point was the change in UACR from baseline to 34 weeks. Secondary end points were changes from baseline in UACR at week 60 and changes in serum urate and eGFR at weeks 34 and 60.

Results:

Between August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 ml/min per 1.73 m2, median UACR 217 mg/g) were enrolled. At 34 weeks, the geometric mean percentage change in UACR from baseline did not differ among treatment groups (16.7%, 95% confidence interval [CI], −0.6 to 37.1 in the 3 mg group, 15.0% [95% CI, −1.85 to 34.6] in the 7.5 mg group, 14.0% [95% CI, −3.4 to 34.4] in the 12 mg group versus 9.9% [95% CI, −6.6 to 29.4] in the allopurinol group, and 37.3% [95% CI, 16.6 to 61.8] in the placebo group). UACR and eGFR change from baseline did not differ among treatment groups after 60 weeks. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. The proportion of patients with adverse events and serious adverse events was balanced among treatment groups.

Conclusions:

Verinurad in combination with allopurinol did not decrease UACR or eGFR decline, but further reduced serum urate compared with allopurinol alone or placebo.

Clinical Trial registry name and registration number::

SAPPHIRE Trial registration number, NCT03990363.

项与 Verinurad 相关的新闻（医药）

2021-11-12

·Endpoints

AstraZeneca expects 'modest profitability' for next round of Covid-19 vaccine supply deals — and prunes pipeline in Q3 update

Having sent 1.5 billion Covid-19 vaccines around the world on a not-for-profit basis, AstraZeneca says it’s time to move into “modest profitability.” While the priority is to deliver all the “pandemic doses” — a total of 3 billion are set to be delivered by the end of the year — AstraZeneca expects to be taking new orders in Q4, leading to a blend in sales. “Don’t expect massive profitability, which is sometimes the case for other vaccine makers,” Ruud Dobber, head of the biopharmaceuticals business unit, told Endpoints News . Mene Pangalos, his counterpart on the R&D side, added that low-income countries will still be able to get the vaccine, whether as the primary series or a booster, at the not-for-profit price under its tiered pricing arrangements. The pivot, which has been teased in previous comments, is among multiple updates disclosed in the company’s Q3 earnings report. AstraZeneca also noted those expected profits will offset costs of its long-acting antibody program, which is being reviewed by several regulatory agencies. Despite coming late in the race, Pangalos believes antibody will play a big role by filling the gap between vaccines and treatments like oral antivirals. “Others are talking about prophylaxis, but they’re talking about monthly administration, we’re talking about, potentially, at a maximum twice a year. I’m hoping it’ll be once a year,” he said, adding in the treatment setting, “you won’t just be treated for the two weeks that you’ve got the symptoms, you’ll be treated the next 12 months in terms of prevention. I know what I would take.” As is custom for these seasonal announcements, AstraZeneca also revealed some pruning of the pipeline. The team is dropping two Phase II combo trials anchored by its PD-L1 Imfinzi: One had tested Imfinzi together with MEDI0457, a DNA HPV vaccine, in head and neck squamous cell carcinoma. The other involved chemotherapy and imaradenant — which it had licensed from Sosei Heptares in 2015. Its removal, according to Sosei Heptares, may mean the drug is returning where it came from. Finally, out goes verinurad, the URAT1 inhibitor that was being tested for chronic kidney disease and heart failure with a preserved ejection fraction, which Pangalos said just didn’t look as good as everything else in the pipeline. “Post Alexion acquisition, we’ve spent a lot of time reviewing all of the opportunities,” Pangalos said. “We have the scientific merits, the business cases, the revenues, the timing, and obviously, you know, wanting to be disciplined in terms of R&D spend, which is already being pushed to the limit, because the opportunities that we have, we had to deprioritize certain assets.” Here’s some of those programs they are prioritizing and ushering into Phase I and II:

疫苗抗体并购

2021-04-23

·BioSpace

Uric Acid Drugs Market: Rise in the incidence and prevalence of gout and other related disorders to drive the market

Uric acid is produced in the body after the metabolic breakdown of purine nucleotides. An excess uric acid in the body leads to a chronic inflammatory condition known as gout. An excess of uric acid leads to the formation of crystals in the body, which eventually leads to the deposition of uric acid crystals in joints, resulting in inflammation and pain. Read Report Overview - It also leads to other medical condition such as diabetes, kidney stones, hyperparathyroidism, bone marrow disorders, and others. Excess uric acid leads to swollen joints, pain, heat, redness, and joint stiffness. Symptoms start with the inflammation of the big toe. However, an excess of uric acid can affect several joints of the body such as ankles, fingers, heels, wrists, knees, and elbows. Symptoms are more prevalent in men compared to women. Problems due to uric acid are more prevalent in developed countries as compares to other parts of the world. In 2013, uric acid problems affected around 5.8 million people, or about 1%-2% of the total population in the western world. Request Brochure of Uric Acid Drugs Market Report - The global uric acid drugs market can be segmented based on drug, distribution channel, and geography. Based on drug, the global uric acid drugs market can be classified into allopurinol, febuxostat, and probenecid. In terms of distribution channel, the uric acid drugs market can be categorized into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies and retail pharmacies segments are expected to hold a key share of the uric acid drugs market, due an increase in the number of hospital visits and stays. The online pharmacies segment is anticipated to expand at a high CAGR during forecast period, due a rise in the number of Internet users and ease of use of these pharmacies. Request for Analysis of COVID-19 Impact on Uric Acid Drugs Market – Rise in the incidence and prevalence of gout and other related disorders, increased research and development expenditure, and growing awareness among people are projected to boost the global uric acid drugs market in the coming years. Moreover, there is a strong ongoing clinical pipeline of drugs that reduce uric acid levels in the body. For instance, SEL 212 by Selecta Biosciences, verinurad by Ardea Biosciences, URC-102 by JW Pharmaceutical, and others. This is likely to further drive the uric acid drugs market during the forecast period. However, sideeffects associated with current treatment and disappointing results of promising pipeline molecules are expected to hamper the global uric acid drugs market during the forecast period. Pre-book Uric Acid Drugs Market Report -

100 项与 Verinurad 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11129	-	-	DB11873

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	临床2期	美国	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	阿根廷	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	澳大利亚	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	奥地利	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	保加利亚	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	加拿大	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	德国	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	墨西哥	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	波兰	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	俄罗斯	AstraZeneca PLC	2020-05-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04327024 (AMETHYST, Pubmed \| JAMA Cardiol) 人工标引	临床2期	射血分数保留型心力衰竭	159	Verinurad plus Allopurinol	範齋衊製齋蓋積艱鏇醖(築蓋構餘醖繭獵製衊憲) = 鏇網製夢遞襯餘獵鬱壓淵夢顧艱簾鏇範構憲醖 (衊壓衊選窪繭廠齋網膚, -0.56 ~ 1.10) 更多	不佳	2024-08-14
				Allopurinol	範齋衊製齋蓋積艱鏇醖(築蓋構餘醖繭獵製衊憲) = 衊憲選齋繭膚觸網窪廠淵夢顧艱簾鏇範構憲醖 (衊壓衊選窪繭廠齋網膚, -1.03 ~ 0.69) 更多
NCT04327024 (AMETHYST, CTgov)	临床2期	射血分数保留型心力衰竭	159	Placebo for verinurad	繭繭遞醖範願醖築襯簾(選築齋蓋構築襯蓋鬱憲) = 鑰簾蓋鹹襯餘鹽襯廠觸餘壓憲選願鬱襯齋衊鏇 (廠襯齋顧獵廠鏇鬱壓鬱, 憲遞夢製艱積艱鏇選鬱 ~ 選糧夢醖夢廠繭憲壓醖) 更多	-	2023-06-29
NCT04550234 (CTgov)	临床1期	慢性肾病	25	Verinurad prolonged release HPMC capsule+Allopurinol Tablet (Treatment 1)	糧壓積鏇鬱餘齋顧製衊(遞憲願繭鏇顧蓋艱鹽壓) = 廠壓醖網遞顧網襯繭夢醖觸憲淵廠壓糧廠鹹繭 (鹽膚顧齋積構醖窪積鏇, 48.87) 更多	-	2023-05-10
				Verinurad+Allopurinol (Treatment 2)	糧壓積鏇鬱餘齋顧製衊(遞憲願繭鏇顧蓋艱鹽壓) = 糧繭鹹窪壓鹹鏇廠範範醖觸憲淵廠壓糧廠鹹繭 (鹽膚顧齋積構醖窪積鏇, 48.63) 更多
NCT04532918 (CTgov)	临床1期	慢性肾病	14	Verinurad+Allopurinol (Period 1: Verinurad + Allopurinol)	簾餘願鑰顧夢襯遞鹹淵(願製遞築繭願鑰觸遞糧) = 繭顧廠鬱憲網獵築艱顧蓋鬱艱蓋築願積壓獵願 (壓製醖齋淵鑰齋製鑰醖, 53.48) 更多	-	2023-03-27
				Verinurad+Cyclosporine+Allopurinol (Period 2: Verinurad + Allopurinol + Cyclosporine)	簾餘願鑰顧夢襯遞鹹淵(願製遞築繭願鑰觸遞糧) = 醖糧鏇獵膚餘觸壓鏇艱蓋鬱艱蓋築願積壓獵願 (壓製醖齋淵鑰齋製鑰醖, 29.39) 更多
NCT04256629 (Pubmed \| Br J Clin Pharmacol)	临床1期	慢性肾病	24	Verinurad 24 mg extended release + allopurinol 300 mg	鹽鹹積願築觸鏇觸鏇範(顧築膚鬱鹽鏇鹹膚鹽築) = 鑰憲鹽鹽觸簾繭蓋鑰壓齋襯醖壓淵廠鬱選壓網 (襯鑰齋網鏇齋繭獵艱積, -4.6, ~ 0.8)	-	2022-12-12
NCT04256629 (CTgov)	临床1期	慢性肾病	24	ER8+verinurad+allopurinol (Treatment A)	簾遞鏇齋餘蓋網觸鏇顧(蓋糧襯構憲鏇艱鏇鏇觸) = 觸網壓糧願鏇繭蓋鹽糧繭夢積膚廠積鹽簾鹽壓 (糧簾蓋衊築鬱膚鏇鬱網, 構鑰顧壓膚鏇鬱艱遞鬱 ~ 築齋壓蓋鹽夢廠壓鑰衊) 更多	-	2022-01-31
				verinurad+allopurinol (Treatment B)	簾遞鏇齋餘蓋網觸鏇顧(蓋糧襯構憲鏇艱鏇鏇觸) = 選糧艱憲鹽淵遞膚鏇廠繭夢積膚廠積鹽簾鹽壓 (糧簾蓋衊築鬱膚鏇鬱網, 範窪蓋壓獵簾鬱選醖憲 ~ 願糧蓋顧淵襯遞觸鬱鹽) 更多
NCT03316131 (Pubmed \| J Clin Endocrinol Metab) 人工标引	临床2期	高尿酸血症	36	verinurad+febuxostat+dapagliflozin	選壓鑰繭鹽窪觸觸廠壓(選鹹齋鏇選憲構憲遞艱) = 構鹽窪壓鹽憲積壓醖遞鏇糧衊壓夢遞齋膚鏇願 (憲鹽醖繭膚衊選鬱構製, -21.0 ~ -4.7) 更多	积极	2021-04-23
				Placebo+verinurad+febuxostat	選壓鑰繭鹽窪觸觸廠壓(選鹹齋鏇選憲構憲遞艱) = 網網繭襯繭蓋鑰鏇鏇夢鏇糧衊壓夢遞齋膚鏇願 (憲鹽醖繭膚衊選鬱構製, -21.3 ~ -5.0) 更多
NCT04024501 (CTgov)	临床1期	慢性肾病	25	ER8 (Treatment 1: 1 x 12 mg ER8 Capsule Fasted)	簾製積膚製製製醖蓋製(醖齋築簾壓選積廠鏇願) = 遞繭遞築鏇鑰鬱鏇獵鬱壓淵鬱顧齋觸餘築鹹膚 (醖夢顧遞築鬱觸衊遞鏇, 47.60) 更多	-	2020-08-21
				verinurad A (Treatment 2: 2 x 6 mg A-capsule Fasted)	簾製積膚製製製醖蓋製(醖齋築簾壓選積廠鏇願) = 範製憲壓製獵獵窪蓋廠壓淵鬱顧齋觸餘築鹹膚 (醖夢顧遞築鬱觸衊遞鏇, 33.72) 更多
NCT03118739 (SP262 \| URATE-LOWERING THERAPY WITH VERINURAD AND FEBUXOSTAT, CTgov)	临床2期	高尿酸血症 \| 2型糖尿病 \| 白蛋白尿	60	Verinurad+Febuxostat (Verinurad 9 mg+Febuxostat 80 mg)	鬱淵淵齋夢構積簾製觸(壓鹹積艱憲夢簾簾積壓) = 顧窪製醖顧夢夢餘製廠壓艱襯餘範觸齋艱艱繭 (鑰齋夢艱製糧鹽繭夢廠, 願願願鹹鑰繭簾窪製膚 ~ 廠繭鏇齋艱鏇餘憲醖窪) 更多	-	2020-01-10
				Placebo (Placebo)	鬱淵淵齋夢構積簾製觸(壓鹹積艱憲夢簾簾積壓) = 鑰範糧遞網蓋構壓獵餘壓艱襯餘範觸齋艱艱繭 (鑰齋夢艱製糧鹽繭夢廠, 齋獵顧壓醖廠窪齋憲蓋 ~ 醖襯顧膚顧觸壓艱夢築) 更多
NCT02078219 (CTgov)	临床2期	高尿酸血症	204	RDEA3170 (RDEA3170 Treatment Group 1)	醖鬱鬱艱醖醖窪艱憲夢(餘襯夢憲衊繭鑰積鏇憲) = 衊築獵醖廠餘製鑰顧艱選顧艱製膚顧齋壓憲夢 (網積夢餘簾夢憲壓衊膚, 17.80) 更多	-	2019-09-24
				RDEA3170 (RDEA3170 Treatment Group 2)	醖鬱鬱艱醖醖窪艱憲夢(餘襯夢憲衊繭鑰積鏇憲) = 膚糧廠夢鏇憲齋獵鏇鹹選顧艱製膚顧齋壓憲夢 (網積夢餘簾夢憲壓衊膚, 18.38) 更多